We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

THERMO FISHER SCIENTIFIC

Thermo Fisher Scientific provides analytical instruments, lab equipment, specialty diagnostics, reagents and integrat... read more Featured Products: More products

Download Mobile App





Thermo Fisher Launches Ion AmpliSeq SARS-CoV-2 Insight Research Assay for SARS-CoV-2 Surveillance

By LabMedica International staff writers
Posted on 08 Jun 2021
Thermo Fisher Scientific Inc. More...
(Waltham, MA, USA) has launched the Ion AmpliSeq SARS-CoV-2 Insight Research Assay to improve SARS-CoV-2 surveillance.

The assay is designed to enable early identification of new and known variants from samples that have lower viral loads. By sequencing more than 99% of the SARS-CoV-2 genome, the assay covers all potential serotypes. The new Ion AmpliSeq SARS-CoV-2 Insight Research Assay broadens and improves local, regional and national surveillance efforts to discover emerging SARS-CoV-2 variants through highly sensitive next-generation sequencing (NGS). Combined with Thermo Fisher's NGS technology, the panel enables researchers to obtain epidemiological insights with rapid turn-around time, workflow automation and seamless informatics and data uploading to public SARS-CoV-2 data repositories.

Optimized to run on the Ion GeneStudio S5 System, the assay includes 237 amplicons specific to SARS-CoV-2, with the addition of variant-tolerant primers for emerging variants. The increased sensitivity of this assay will empower researchers to sequence the complete genome and discover new variants from a variety of sample types including nasophyrengeal and shallow nasal swabs, saliva and others, and with cycle threshold (Ct) values higher than 28, or as low as 50 viral copies. To further expedite NGS analysis of SARS-CoV-2 and to help meet growing customer demand, Thermo Fisher has begun optimizing the Ion AmpliSeq SARS-CoV-2 Insight Research Assay for the Ion Torrent Genexus System. Launched in November 2019, the company's newest sequencing platform automates the entire targeted NGS workflow and can deliver specimen to report economically in just one day. Optimization and validation of the research assay on the Genexus System is now underway in collaboration with Thermo Fisher customers.

"RNA viruses such as SARS-CoV-2 mutate at high rates in response to selective environmental pressures, requiring labs and vaccine developers to monitor mutations diligently," said Andy Felton, vice president of clinical next generation sequencing at Thermo Fisher. "Higher sensitivity next-generation sequencing assays are needed to identify mutations earlier in both symptomatic and asymptomatic individuals to help public health officials and labs globally track the spread of new and known variants for public health decisions and guidance locally."



Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Collection and Transport System
PurSafe Plus®
New
Capillary Blood Collection Tube
IMPROMINI M3
New
Gold Member
Collection and Transport System
PurSafe Plus®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The nanotechnology-based liquid biopsy test could identify cancer at its early stages (Photo courtesy of 123RF)

2-Hour Cancer Blood Test to Transform Tumor Detection

Glioblastoma and other aggressive cancers remain difficult to control largely because tumors can recur after treatment. Current diagnostic methods, such as invasive biopsies or expensive liquid biopsies,... Read more

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Pathology

view channel
Image: An adult fibrosarcoma case report has shown the importance of early diagnosis and targeted therapy (Photo courtesy of Sultana and Sailaja/Oncoscience)

Accurate Pathological Analysis Improves Treatment Outcomes for Adult Fibrosarcoma

Adult fibrosarcoma is a rare and highly aggressive malignancy that develops in connective tissue and often affects the limbs, trunk, or head and neck region. Diagnosis is complex because tumors can mimic... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.